Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

789
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
789
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.4K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.4K
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

806
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
806
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

1.0K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.0K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

766
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
766
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of malignancy-related ascites.

Oncology nursing forum·2014
Same author

Historical perspective on the progress of chemotherapy-induced nausea and vomiting treatment in oncology nursing forum.

Oncology nursing forum·2013
Same author

Management of pancreatic exocrine insufficiency.

Oncology nursing forum·2013
Same author

Management of diabetes and pancreatic cancer.

Oncology nursing forum·2012
Same journal

Exploring Information Needs of Patients With Cancer and Family Caregivers: A Descriptive and Network Analysis of End-of-Life Inquiries.

Oncology nursing forum·2026
Same journal

Postoperative Physiologic Comfort Management for Patients With Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy.

Oncology nursing forum·2026
Same journal

Exploring Racial Disparities in Uterine Cancer Survival: A 20-Year, Single-Site Analysis.

Oncology nursing forum·2026
Same journal

What I See as an Editor: The Reach of Nurse-Led Intervention Oncology Research.

Oncology nursing forum·2026
Same journal

Trends and Hot Spots in Cancer Family Resilience: A Bibliometric and Visualization Study.

Oncology nursing forum·2026
Same journal

Seven-Year Cognitive Trajectories in Older Adult Cancer Survivors: Findings From a National Cohort Study.

Oncology nursing forum·2026
See all related articles

Related Experiment Video

Updated: Apr 21, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

1000

Carcinoid heart disease.

Anne Marie C Flaherty1

  • 1Gastrointestinal Oncology Division, John Theurer Cancer Center, Hackensack University Medical Center, New Jersey.

Oncology Nursing Forum
|October 31, 2014
PubMed
Summary
This summary is machine-generated.

This case study details a 59-year-old woman with metastatic carcinoid tumor of the terminal ileum. The functional tumor caused hormonal hypersecretion, leading to various symptoms and requiring extensive treatment over eight years.

Keywords:
carcinoidgastrointestinalhearttumor

More Related Videos

Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

28.4K

Related Experiment Videos

Last Updated: Apr 21, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

1000
Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

28.4K

Area of Science:

  • Oncology
  • Gastroenterology
  • Endocrinology

Background:

  • A 59-year-old female patient was diagnosed with metastatic carcinoid tumor of the terminal ileum in May 2003.
  • The patient underwent extensive surgical resection including hemicolectomy, cholecystectomy, distal pancreatectomy, and splenectomy due to metastatic disease in the pancreas, mesentery, and liver.

Observation:

  • The patient's tumor was functional, exhibiting hormonal hypersecretion.
  • Symptoms included flushing, diarrhea, bronchospasm, and abdominal pain.
  • Intermittent pleural effusions and a trace pericardial effusion were noted, not requiring intervention.

Findings:

  • Over eight years, the patient received multiple treatments: octreotide, everolimus, oxaliplatin, and hepatic artery embolizations.
  • Recent treatment involved capecitabine and bevacizumab with monthly octreotide.
  • The case highlights the complex management of metastatic carcinoid tumors.

Implications:

  • This case underscores the challenges in managing advanced, functional neuroendocrine tumors.
  • It demonstrates the multidisciplinary approach required for long-term patient care.
  • Understanding tumor behavior and treatment response is crucial for optimizing outcomes in metastatic carcinoid disease.